Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit.

ABSTRACT:

Background

Almost 100 novel cancer medicines have been approved in Europe over the last decade. Limited public health care resources in countries in Central and Eastern Europe (CEE) call for a prioritization of access to effective medicines. We investigated how both reimbursement status and waiting time to reimbursement correlate with the magnitude of clinical benefit provided by novel medicines in four selected countries (Czechia, Hungary, Poland, and Slovakia).

Materials and methods

A total of 124 indications of 51 cancer medicines with marketing authorization by the European Medicines Agency in 2011-2020 were included and followed up until 2022. Data on reimbursement status and waiting time to reimbursement (i.e. time from marketing authorization to national reimbursement

SUBMITTER: Hofmarcher T 

PROVIDER: S-EPMC10485399 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature